ARTICLE | Clinical News
PV-10: Completed Phase I enrollment
March 23, 2015 7:00 AM UTC
Provectus completed enrollment of 15 patients in an open-label, U.S. Phase I trial evaluating intratumoral PV-10. Patients will have surgery to remove their tumors about 7-14 days after receiving PV-1...